Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBITDA Margin: 2015-2025

Historic EBITDA Margin for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -325.44%.

  • Editas Medicine's EBITDA Margin rose 10732374.00% to -325.44% in Q3 2025 from the same period last year, while for Sep 2025 it was -428.71%, marking a year-over-year decrease of 5868.00%. This contributed to the annual value of -777.22% for FY2024, which is 56067.00% down from last year.
  • Per Editas Medicine's latest filing, its EBITDA Margin stood at -325.44% for Q3 2025, which was up 77.41% from -1,440.58% recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's EBITDA Margin peaked at -39.90% during Q4 2023, and registered a low of -136,952.38% during Q3 2022.
  • Its 3-year average for EBITDA Margin is -12,195.06%, with a median of -1,440.58% in 2025.
  • Per our database at Business Quant, Editas Medicine's EBITDA Margin slumped by 13,631,896bps in 2022 and then skyrocketed by 13,601,229bps in 2023.
  • Over the past 5 years, Editas Medicine's EBITDA Margin (Quarterly) stood at -333.71% in 2021, then crashed by 63,701bps to -970.72% in 2022, then spiked by 93,081bps to -39.90% in 2023, then crashed by 11,234bps to -152.24% in 2024, then soared by 10,732,374bps to -325.44% in 2025.
  • Its EBITDA Margin was -325.44% in Q3 2025, compared to -1,440.58% in Q2 2025 and -1,635.10% in Q1 2025.